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Abstract
KCNMA1 encodes the a-subunit of the large conductance, voltage and Ca2+-activated (BK) potassium channel and has been
reported as a target gene of genomic amplification at 10q22 in prostate cancer. To investigate the prevalence of the
amplification in other human cancers, the copy number of KCNMA1 was analyzed by fluorescence-in-situ-hybridization
(FISH) in 2,445 tumors across 118 different tumor types. Amplification of KCNMA1 was restricted to a small but distinct
fraction of breast, ovarian and endometrial cancer with the highest prevalence in invasive ductal breast cancers and serous
carcinoma of ovary and endometrium (3–7%). We performed an extensive analysis on breast cancer tissue microarrays
(TMA) of 1,200 tumors linked to prognosis. KCNMA1 amplification was significantly associated with high tumor stage, high
grade, high tumor cell proliferation, and poor prognosis. Immunofluorescence revealed moderate or strong KCNMA1
protein expression in 8 out of 9 human breast cancers and in the breast cancer cell line MFM223. KCNMA1-function in breast
cancer cell lines was confirmed by whole-cell patch clamp recordings and proliferation assays, using siRNA-knockdown, BK
channel activators such as 17ß-estradiol and the BK-channel blocker paxilline. Our findings revealed that enhanced
expression of KCNMA1 correlates with and contributes to high proliferation rate and malignancy of breast cancer.
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Introduction
BK (KCNMA1) potassium channels are a diverse class of ion
channels expressed in many different cell types [1]. They modulate
numerous physiological processes in excitable and non-excitable
tissues and take part in forming macromolecular signaling
complexes [2,3]. The protein encoded by KCNMA1 represents
the pore-forming a subunit of the a-subunit of the large
conductance, voltage and Ca2+-activated (BK) K+ channel. The
a-subunit can form macromolecular complexes with four different
types of auxillary b-subunits and local Ca2+ influx channels [4].
Because of the large number of protein interactions and activating
factors influencing BK channel function, including intracellular
Ca2+, membrane voltage, pH, shear stress, carbon monoxide,
phosphorylation states, as well as G-proteins and steroid
hormones, it is generally difficult to predict the role of BK
channels in a given tissue [5]. Moreover, phosphatidylinositol 4,5-
bisphosphate (PIP2), PI3K and PTEN can regulate BK channel
activity [6,7]. Finally, BK channel function and pharmacological
properties are fine-tuned by differential splicing and depend on the
presence of auxiliary b-subunits (b1–b4) [8].
In many diseases, defective regulation/or expression of BK
channels have repeatedly been associated with altered cell cycle
progression [9], cell proliferation [10,11,12,13,14,15,16], and cell
migration [17,18]. These factors are fundamental to the development
of cancer [19,20]. As demonstrated in electrophysiological studies on
cervical and breast cancer cells, BK channels are directly activated by
estrogens, which have an essential role in cancers of the uterus, breast
and prostate [21,22]. Specific blockade of BK channels leads to
membrane depolarization, cell cycle progression and inhibition of cell
proliferation [1,23]. Early reports pointed to high levels of
KCNMA1-expression in human glioblastomas [24]. A number of
subsequent reports pointed to a more general role of BK channels in
different types of cancer, although this not seems to apply to all
(Cambien et al., 2008). We previously detected genomic amplification
of the BK channel encoding gene KCNMA1 in 16% of late-stage
prostate cancers, identifying KCNMA1 as one of the most common
amplifications in prostate cancer [13]. We found that knockdown of
KCNMA1 by siRNA and specific BK channel blockade by iberiotoxin
inhibited cell proliferation of the prostate cancer cell line PC3, which
carries an amplification of KCNMA1. This study suggested a specific
role of KCNMA1 in the transition from hormone-sensitive to
hormone-insensitive and castration-refractory prostate cancer [13].
The aim of this study was to investigate the prevalence of
KCNMA1 amplification in cancers beyond prostate cancer, and to
explore its functional and prognostic consequences.
Methods
Fluorescence in situ hybridization (FISH), probes, and
clinical specimens
The bacterial artificial chromosome (BAC) RP11-428p16,
which contains major parts of the KCNMA1 gene sequence and
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CEP 10 (Spectrum orange labelled; Vysis), were utilized as
described previously (Bloch et al., 2006). The following criteria
were applied for amplified FISH-amplified results: KCNMA1-
probe/centromer 10-signal ratio of at least 2, and at least 5 signals
of KCNMA1-probe.
Tissue Microarrays (TMA)
Formalin-fixed and paraffin-embedded clinical specimens from
the archive of the Institute of Pathology, University Hospital Basel,
Switzerland, were used for the construction of all TMAs [25]. The
breast cancer TMA was constructed from a total of 2’222
formalin-fixed, paraffin-embedded tumours, as previously de-
scribed [26]. The median patient age was 62 (range, 26–101) years
and the mean follow-up time was 68 months (range, 1–176). The
information on the clinical follow-up were retrieved from the
patient charts. Tumour data regarding histologic subtype, TNM
classification, Bloom-Richardson- Elston-Ellis (BRE) grade, and
diameter were obtained from pathology reports. Additionally,
frozen breast cancer specimens were used for immunofluores-
cence. This study was approved by the ethical committee Basel
(EK 142/09). According to the decision of the ethical committee a
written informed consent by the patients was not needed due to
the retrospective nature of the study.
Cell lines and cell culture
T47D [27], SKBR3 [28] and PC3 [13] cell lines were obtained
from American Type Culture Collection (ATCC, LGC Promo-
chem, Molsheim Cedex, France) and grown under standard cell
culturing conditions in Optimem cell culture medium (Invitrogen,
Carlsbad, CA), supplemented with 1% penicillin/streptomycin
(Amimed, Basel, Switzerland) and 10% FCS (Amimed) at 37uC/
5% CO2. Trypsin-EDTA (Amimed) was used as a transferring
reagent. Cell lines MFM223 [29], MCF7 [30], LNCaP [13] and
BPH1 [13] were obtained from German Collection of Microor-
Table 1. Amplification of KCNMA1 in tumours.
Tumor entity subtype n amp amp (%)
1. Skin 151 0 0
2. Respiratory tract 136 0 0
3. Gynecological tract 599 10 1.7
endometrium serous carcinoma 30 1 3.3
endometrium endometrioid carcinoma 46 0 0
endometrium stromal sarcoma 3 0 0
endometrium carcinosarcoma 26 0 0
breast ductal carcinoma 44 3 6.8
breast medullary carcinoma 43 2 4.7
breast lobular carcinoma 28 0 0
breast mucinous carcinoma 34 0 0
breast tubular carcinoma 26 0 0
breast cribriform carcinoma 21 0 0
breast apocrine carcinoma 10 0 0
breast phyllodes tumor 35 0 0
ovary malignant mu¨llerian mixed tumor 4 1 25.0
ovary serous carcinoma 48 3 6.3
ovary mucinous carcinoma 26 0 0
ovary Brenner tumor 21 0 0
ovary endometroid carcinoma 14 0 0
vagina squamous cell carcinoma 19 0 0
vulva squamous cell carcinoma 54 0 0
cervix squamous cell carcinoma 43 0 0
cervix adenocarcinoma 22 0 0
cervix adenosquamous carcinoma 2 0 0
4. Gastrointestinal tract 383 0 0
5. Urogenital tract 239 0 0
6. Endocrine organs 161 0 0
7. Haematolymphatic system 116 0 0
8. Brain 171 0 0
9. Soft tissue 216 0 0
Sum 2172 10 0.5
FISH analysis in a multi-tumour TMA with 2445 specimens from 118 different tumour types. The amplification was restricted to a small fraction of breast cancer and rare
cases of ovarian and endometrial cancer.
doi:10.1371/journal.pone.0041664.t001
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ganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and
grown under the same conditions. In case of MCF7, the Optimem
medium was replaced by RPMI 1640-cell culture medium. PC346
[31] and PC3456C [31] were obtained from G. Jenster
(Department of Urology, Josephine Nefkens Institute, Erasmus
Medical Center, P.O. Box 1738, 3000 DR, Rotterdam, The
Netherlands) and grown under standard conditions.
RNAi and proliferation assays
Transfection was performed following the small-interferent
RNA (siRNA) sequences transfection protocol for Lipofectamine
2000 (Qiagen, USA). 4 hours after transfection cell culture
medium was replaced and supplemented with 10% FCS, to
trigger normal cell growth. Nonsense RNAi (nsRNA) was used as a
negative control for KCNMA1 siRNA. Relative levels of
KCNMA1 expression were determined in replicate cultures by
real-time PCR. For proliferation assays replicate cultures were
grown in parallel, to allow repeated cell harvesting and counting.
Cell counting was performed, using a ‘CASY’ cell counter
(Innovatis, Reutlingen, Germany) and standard counting proce-
dures were followed to determine cell quantity. The efficiency of
the RNAi on KCNMA1 knock-down was controlled in replicate
cultures that were grown in parallel.
Immunofluorescence of frozen tissue samples, cytospins
and microscopy
Trypsinized cells were harvested and washed in PBS twice.
Aliquots of 100 mL were centrifuged for 2 minutes and dried with
a ventilator. Frozen tissue samples and cytospins were incubated
with an anti-KCNMA1 polyclonal antibody and prepared as
previously described [13]. Images were obtained using a Zeiss
Axioplan 2 fluorescence microscope (Zeiss, Jena, Germany),
equipped with an appropriate filter set. The selection of target
cells was based on clear visibility in DAPI-staining. An ISIS-digital
camera (MetaSystems, Altlussheim, Germany) was set up to
Figure 1. Amplification of KCNMA1 in breast cancer. FISH
analysis of KCNMA1 in amplified (left) and non-amplified (right) breast
cancer specimens (magnification61000).
doi:10.1371/journal.pone.0041664.g001
Table 2. Amplification of KCNMA1 in breast cancer.
Breast cancer subtype n amp amp (%)
papillary 18 1 5.6
cribriform 36 1 2.8
invasive ductal 881 20 2.3
invasive lobular 139 1 0.7
medullary 37 0 0
tubular 35 0 0
mucinous 31 0 0
apocrine 7 0 0
clear-cell 5 0 0
medullary atypical 4 0 0
metaplastic 5 0 0
neuroendocrine 2 0 0
Sum 1200 23 1.9
Summary of the results from FISH analysis of KCNMA1-amplification in 1200
breast cancers.
doi:10.1371/journal.pone.0041664.t002
Figure 2. Expression of KCNMA1 (micrographs). Immunofluores-
cence on a frozen tumour tissue sample and cytospins of different cell
lines. Stainings represent BK-specific antibody (green) and DAPI (blue).
Positive KCNMA1-staining in a KCNMA1-amplified frozen breast cancer
specimen (A), positive staining in KCNMA1 amplified MFM223 at low (B)
and high (C) magnification, negative staining in MCF7 (D) and T47D (E)
at low magnification, and positive staining of the KCNMA1 amplified
prostate cancer cell line PC3 (F; positive control) shown at high
magnification. Bar = 10 mm.
doi:10.1371/journal.pone.0041664.g002
Figure 3. Expression of KCNMA1. Immunofluorescence in amplified
(n = 3) and non-amplified (n = 6) breast cancer tissue sections. KCNMA1
expression was scored independently by two persons. Bars represent
average scores (scores ranged from: 0, 1, 2, to 3).
doi:10.1371/journal.pone.0041664.g003
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capture multi-stack images. The resultant images were resized,
cropped and had their levels and contrast adjusted accordingly.
PBS-washed slides were used as negative controls.
Immunohistochemistry
Standard indirect immunoperoxidase procedures were used for
the detection of Ki67 (clone MIB1, prediluted, DAKO, Glostrup,
Denmark), estrogen receptor-a (ER-a clone 6F11, dilution
1:1’000, Novocastra Laboratories, Newcastle, UK) and androgen
receptor (AR clone 156C135.1, dilution 1:50, Imgenex Corp., San
Diego, USA) in paraffin-embedded PCA tissue sections by
standard protocols, as previously described [32]. Ki67 LI was
defined as the fraction of tumour cells showing any nuclear Ki67
immunoreactivity. 100 tumour cells were counted per tissue spot
to determine the Ki67 LI. Analysis was performed using Bond
Max automated immunohistochemistry slide staining system
(Leica Microsystems GmbH, Germany).
RNA extraction and cDNA synthesis, quantitative RT-PCR
Total RNA from cell lines was extracted using RNeasy Mini Kit
(QIAGEN, Hilden, Germany) according to the instructions of the
manufacturer. RNA concentrations were determined with Nano-
drop spectrophotometer (Witec AG, Littau, Switzerland). Real-
time PCR was performed using the LightCycler system and
LightCycler FastStart DNA Master Hybridization Probes kit
(Roche, Hilden, Germany). Primers were obtained from TIB
MolBiol (Berlin, Germany): KCNMA1-for: TggCCTCCTCC-
ATggTgA, KCNMA1-rev: TTCTgggCCTCCTTCgTCT, GAP-
DH-for: gAAggTgAAggTCggAgTC, GAPDH-rev: gAAgATggT-
gATgggATTTC, KCNMA1-FL: AgCgTCCgCCAgAgCAAgAT-
FL, KCNMA1-LC: LC640-ATgAAgAggCCCCCgAAgAAAgT-
PH, GAPDH-FL: AggggTCATTgATggCAACAATATCCA-FL,
GAPDH-LC: LC640-TTTACCAgAgTTAAAAgCAgCCCTggT-
g-PH. PCR conditions were: Activation 10 min 95uC, annealing
5 s at 54uC, elongation 15 s at 72uC, 40 cycles. Relative levels of
expression (normalized against GAPDH) were determined ac-
cording to [33].
Patch clamping
MCF-7 and MFM-223 cells grown on glass cover slips were
mounted on the stage of an inverted microscope (IM35, Zeiss,
Go¨ttingen, Germany), kept at 37uC and continuously perfused
with Ringer solution of the following composition (mmol/l): NaCl
145, KH2PO4 0.4, K2HPO4 1.6, D-glucose 5, MgCl2 1, Ca-
gluconate 1.3, pH 7.4). Experiments were performed in the fast
whole cell configuration as described previously [13]. In brief, cells
were voltage clamped from 260 to +40 mV and patch pipettes
had an input resistance of 2–4 MV, if filled with a solution
containing (mM): KCl 30, K-gluconate 95, NaH2PO4 1.2,
Na2HPO4 4.8, EGTA 1, Ca-gluconate 0.758, MgCl2 1.034, D-
glucose 5, ATP 3. The pH was set to 7.2 and Ca2+ activity was
0.1 mM. The access conductance was measured continuously,
remaining between 60–100 nS. Membrane conductance Gm was
calculated from the measured current (I) and Vc values according
to Ohm’s law.
Materials and statistics
17b-estradiol (Sigma-Aldrich, Buchs, Switzerland) was dissolved
in 100% ethanol to build a stock solution of 0.5 mM, which was
further diluted to a final concentration of 10 nM, using the
appropriate cell culture medium. Paxilline (Sigma-Aldrich, Buchs,
Switzerland) was dissolved in 100% DMSO to build a stock
solution of 50 mM, and then further diluted in phenol red-free
medium supplemented with 5% dextran-coated charcoal-stripped
FCS [27] to a final concentration of 15 mM. Prior to the
experiments, standard growth curves were calculated to adjust
optimal conditions for all cell lines and reagents, respectively. For
all patch clamp experiments, Student’s t-test P-values,0.05 were
accepted to indicate statistical significance (*).
Results
Large-scale FISH analysis on multi-tumour and breast
cancer TMA
Previously, we reported amplification of KCNMA1 in 16% of
advanced-stage human prostate cancers [13]. In the present study,
we examined the prevalence of the KCNMA1 amplification in the
whole range of human cancer and analyzed a large multi-tumour
TMA, containing 2445 tissue spots from 118 different tumour
types by FISH, using a KCNMA1-specific BAC probe (Table 1).
FISH was successful in 2172 samples (88.8%). Amplification of
KCNMA1 was restricted to 10 of 603 (1.7%) gynecological tumours
known to be influenced by estrogens (Table 1, Figure 1). Using
FISH, the results were validated on a large breast cancer TMA
(Table 2). Amplification of KCNMA1 was found in 23 of 1200
Table 3. Relationship between KCNMA1 amplification,
proliferation, and expression of AR.
score KCNMA1
amplified non-amplified
Ki67 LI* low 2/9 (22%) 19/25 (76%)
high 7/9 (78%) 6/25 (24%)
AR-IHC** 2 8/9 (89%) 11/25 (44%)
+ 1/9 (11%) 14/25 (56%)
*Ki67 LI: scores range from 0 to 90, low scores ,30, high scores $30.
**IHC: AR-status scored negative or positive.
Percentage of tumours with high ($30%) and low (,30%) Ki67 labelling index
(LI). Amplification of KCNMA1 was associated with high Ki67 LI (p,0.002) and
AR negative IHC status (p,0.05).
doi:10.1371/journal.pone.0041664.t003
Figure 4. Association of KI67 with KCNMA1. Mean values from
MIB1 (Ki67)-staining in 34 breast cancers, which have been analysed by
FISH. The results reveal a significant association between KCNMA1 and
fast tumour growth in breast cancer (p,0.002).
doi:10.1371/journal.pone.0041664.g004
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breast cancers (1.9%) and was significantly associated with high
tumour grade (p,0.001), high tumour cell proliferation (p,0.01)
and poor tumour-specific survival (Log-Rank p= 0.031).
Analysis frozen sections from nine human breast cancers by
immunofluorescence revealed strong expression of BK channels in
seven, and weak expression in two specimens. There was no
correlation between amplification of KCNMA1 and BK expression
in these specimens, suggesting that KCNMA1 can also be up
regulated by mechanisms other than genomic amplification
(Figure 2). The KCNMA1-amplified breast cancer (MFM223)
and prostate cancer (PC3; positive control) cell lines were strongly
positive for BK channels, while non-amplified breast cancer cell
lines T47D and MCF7 were only weakly positive or negative as
evaluated by immunofluorescence (Figure 3).
Association between KCNMA1 amplification and cell
proliferation, ER-a and AR expression
To explore the association between amplification of KCNMA1
and tumour cell proliferation, we constructed a TMA with 34
specimens enriched for KCNMA1 amplified breast cancers (9 with
and 25 without KCNMA1 amplification) using two tissue cores per
specimen. The specimens were also analyzed by IHC for
expression of ER-a, AR and Ki67 (Mib1). KCNMA1 amplification
was significantly associated with high tumour cell proliferation
(defined as Ki67 LI.30%; p,0.002) (Table 3, Figure 4).
Interestingly, a positive AR expression was detected in 14 of 25
(56%) of the non-KCNMA1 amplified tumours but in only one of
nine (11%) KCNMA1 amplified tumours (p,0.05). Immunohisto-
chemical AR positivity was not associated with proliferation (data
not shown). ER-a was not associated with KCNMA1-amplifica-
tion status of Ki67 (data not shown).
Association between KCNMA1 amplification and BK
mRNA expression
We analyzed the expression profile of BK-mRNA using
quantitative real-time PCR in 26 different cancer cell lines. All
samples were normalized against GAPDH [33]. KCNMA1
amplified breast (MFM223) and prostate (PC3) cell lines revealed
highest expression of BK-mRNA, with transcript levels in
MFM223 being over 100-times higher than in MCF7
(Figure 5). The T47D cell line harbors a deletion of GAPDH
and was therefore excluded from further analysis. Since amplifi-
cation of KCNMA1 was restricted to gynecological and prostate
cancers, we tested the association between BK-mRNA levels in cell
lines originating from (a) hormone sensitive versus (b) hormone
insensitive organs. The average rank of KCNMA1-mRNA
expression was significantly higher in class (a) than in class (b)
(19.1 versus 8.7; p,0.001; Wilcoxon signed-rank test) (Table 4).
Contribution of BK channels to cell proliferation
To investigate its functional role for cell proliferation, we
knocked down KCNMA1 in the cell lines MFM223, MCF7 and
T47D using KCNMA1-specific siRNA. Knocking down
KCNMA1 reduced proliferation by 58% (T47D), 35% (MCF7),
and 13% (MFM223) (Figure 6). The knockdown efficiencies were
between 75–86% (measured after 24–48 h) across all analyzed cell
lines (data not shown). Similarly, pharmacological inhibition of BK
channels by paxilline decreased cell proliferation rate by 54%
(T47D) and 21% (MCF7), but surprisingly enhanced proliferation
by 42% in MFM223 cells, accompanied by a noticeable change in
the cell morphology (Figure 7). In comparison, proliferation of
the KCNMA1-amplified prostate cancer cell line PC3 was strongly
reduced by both treatments (Figure 6). To test whether female
sex hormone derivates increase the cell proliferation rate in these
cell lines, we performed experiments in the presence of 17b-
Figure 5. Amplification of KCNMA1 in cancer cell lines. Expression profiles of 26 cancer cell lines, derived from different tissue types
(quantitative real-time PCR analysis). KCNMA1 amplified cell lines MFM223 and PC3 showed the highest expression.
doi:10.1371/journal.pone.0041664.g005
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estradiol. 17b-estradiol is described to be an activator of BK
channels and increased cell proliferation in MCF7, but not in
T47D, MFM223 or PC3 cells (Figure 6).
Functional analysis of BK channels in breast cancer cell
lines
Electrophysiological analysis revealed that BK K+ currents were
present in both MCF7 and MFM223 cell lines. Furthermore, we
found that 17b-estradiol stimulated whole-cell K+ outward
currents in both cell lines resulting in a hyperpolarisation of their
membrane potential (Figure 7 A,C). While low (‘‘physiological’’)
concentration (10 nM) of 17b-estradiol was sufficient to activate
BK K+ currents in MCF7 cells, stimulation of KCNMA1-driven
K+ currents in MFM223 cells required a 1000-fold higher (‘‘non-
physiological’’) concentration (10 mM). This finding suggests a
different sex hormone-sensitivity towards KCNMA1 stimulation in
these cell lines (Figure 8 B–D). A direct activator of KCNMA1,
NS1619 (10 mM), clearly activated BK currents in MFM223 cells,
but had little effects in MCF7 cells (Figure 8 E,F). K+ outward
currents activated by 17b-estradiol or NS1619 were inhibited by
the BK channel blocker paxilline (5 mM). Taken together, these
results indicate that breast cancer cells exhibit functional BK
currents. Fast proliferating MFM223 cells have larger KCNMA1
currents with pharmacological properties different to MCF7 cells,
possibly due to differential expression of ß-subunits (KCNMB1-4).
To verify the above presented results based on the use of
pharmacological tools, RNA-interference was performed using
siRNA against KCNMA1 to suppress KCNMA1-currents in both
MCF7 and MFM223 cells. While 17b-estradiol clearly activated
whole-cell K+ outward currents in non-treated MCF7 (10 nM)
and MFM223 (10 mM) cells and in cells transfected with
scrambled RNA, K+ current activation by 17b-estradiol was
strongly reduced in both cell lines after siRNA-knockdown of
KCNMA1 (Figure 9 C).
Discussion
Our study reveals for the first time that KCNMA1 amplification
is restricted to human cancer types that derive from tissues
regulated by sex steroid hormones including prostate, breast,
uterus, and ovary. In breast cancer, KCNMA1 is amplified in a rare
subgroup of breast cancers with poor prognosis. Moreover, our
data suggest that 17b-estradiol can induce proliferation of breast
cancer cells through activation of BK channel.
K+ channels control cellular functions that determine tumour
malignancy such as cell cycle and survival, proliferation, and
migration. Previous studies have firmly established that different
types of K+ channels exhibit oncogenic potential
[10,11,12,13,14,15,16]. Large conductance, voltage- and Ca2+-
activated potassium channel (KCNMA1; BK) is located at 10q22.3
and was recently found to be amplified in a proportion of
castration-refractory human prostate cancers, suggesting an
involvement in the progression of the disease [13]. In the present
study, we investigated the prevalence of the KCNMA1 amplifica-
tion beyond prostate cancer. Our findings provide the first
evidence that breast, ovarian and endometrial cancers carry also
KCNMA1 amplification. Highest prevalence was found in invasive
ductal breast cancer and serous carcinoma of the ovary and
endometrium (3–7%). Our results demonstrate that KCNMA1
amplification is associated with high tumour stage, high tumour
grade, high tumour cell proliferation, and poor prognosis.
KCNMA1 was amplified in MFM223, a rapidly growing
metastatic human breast cancer cell line, and associated with
strongly up-regulated mRNA- and protein expression. KCNMA1-
mRNA expression was by far highest in MFM223 among all 26
analyzed cancer cell lines using quantitative real-time PCR, and
more than 100-fold higher than in the non-amplified breast cancer
cell line MCF7. Thus, it appears paradoxical that there was no
inhibition of proliferation by siRNA or paxilline in MFM223 as
opposed to the breast cancer cell lines MCF7 and T47D. One
could hypothesize that the massive overexpression renders the
MFM223 cells resistant to inhibition. Moreover this cell line
essentially grows estrogen independent and demonstrates phar-
macological properties different to other BK-expressing cancer
cells, which is possibly due to differential expression of ß-subunits.
In contrast to MCF7 and T47D, MFM223 has a low ER and PR
expression but a very strong AR expression, [27,34]. This indicates
that the sex hormone receptor status might also affect the response
of breast cancer cells to inhibition of BK channel.
Although expression and function of KCNMA1 is related to cell
cycle control and correlates with proliferation and migration, it is
not a simple task to unravel the underlying mechanisms [10]. BK
channels interact with a large number of proteins, regulatory
factors and second messenger pathways, which makes it difficult to
predict a general role for KCNMA1 in different tissues. Moreover
experimental conditions necessarily differ between the methods
used to examine the role of channel expression and function for
Table 4. Cell lines.
Class Cell line Designation Source Tissue of origin
(a) MFM-223 ACC-422 DSMZ breast
(a) SK-BR-3 HTB-30 ATCC breast
(a) MCF-7 HTB-22 NCI-60 breast
(a) OVCAR-3 HTB-161 ATCC ovary
(a) OVCAR-8 - NCI-60 ovary
(a) OVCAR-4 - NCI-60 ovary
(a) Onco-DG1 ACC-507 DSMZ ovary
(a) PC3 CRL-1435 ATCC prostate
(a) PC-346C - Rotterdam prostate
(a) PC-346 - Rotterdam prostate
(a) LNCaP CRL-1740 ATCC prostate
(a) BPH-1 ACC 143 DSMZ prostate
(b) 5637 HTB-9 DSMZ bladder
(b) HT-1376 CRL-1472 ATCC bladder
(b) CRL-7930 - ATCC bladder
(b) SCaBER HTB-3 ATCC bladder
(b) TCC-SUP HTB-5 ATCC bladder
(b) RT112-D21 - ATCC bladder
(b) ME-180 - CTCC cervix
(b) Caco-2 CCL-185 ATCC colon
(b) RKO CRL-2577 ATCC colon
(b) SW-480 CCL-228 ATCC colon
(b) SK-HEP-1 HTB-52 ATCC liver
(b) HEP-G2 HB-8065 ATCC liver
(b) SK-MEL-2 HTB-68 ATCC skin
(b) S-117 ACC-266 DSMZ thyroid
Cell lines originating (a) with frequent and (b) without expression of sex
hormone receptors.
doi:10.1371/journal.pone.0041664.t004
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cell proliferation, e.g. patch clamp experiments are done in the
absence of serum [10].
Along this line, in the non-estrogen sensitive MFM223 cells, BK
currents were activated only by non-physiologically high concen-
trations of 17b-estradiol, while low concentrations (10 nM) were
sufficient to activate BK currents in MCF7 cells. A direct activator
of KCNMA1, NS1619 (10 mM), significantly activated BK
currents in MFK223 but not in MCF7 cells. These results suggest
that, apart from differences in the level of KCNMA1 expression,
there are probably differential expression levels of KCNMB1-4
subunits in both cell lines, which may lead to differential sensitivity
towards physiological agonists (17b-estradiol) and pharmacological
compounds (NS1619). Alternative pre-mRNA splicing is another
mechanism that could explain different function of BK channels in
different tissues, tumour types and cellular conditions [35]. For
example, it has been shown that estrogen can influence the
response of KCNMA1 to protein kinase A by differentially
regulating the expression of a splice variant in rat myometrium
[36].
The restriction of KCNMA1 amplification to carcinomas from
sex hormone-regulated organs is highly intriguing and also
suggests an interaction of KCNMA1 within the hormonal context
of these tumours. This is supported by our data, showing that 17b-
estradiol induces cell proliferation in MCF7 and functional
activation of BK channel in MCF7 and MFM223, which is
abrogated by siRNA or by paxilline. This is also in line with a
previous study where the BK blocker iberiotoxin lead to reduced
proliferation in the breast cancer cell line MDA-MB-231 [37]. In
addition, it has been shown that BK channel activity in MCF7 can
be stimulated by tamoxifen, a therapeutic ER antagonist with
Figure 6. Proliferation of breast cancer cells. Proliferation rates of MCF7, T47D, MFM223 and PC3 in response to siRNA targeting KCNMA1, BK-
channel blocker paxilline and 17b-estradiol (E2). Proliferation rates of MCF7 and T47D were significantly reduced by siRNA and paxilline. MFM223 did
not show a similar reduction after RNAi and strongly increased the proliferation rate upon treatment with paxilline; * p,0.05, ** p,0.01, n.s. = not
significant.
doi:10.1371/journal.pone.0041664.g006
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partial agonistic activity, leading to increased cellular proliferation
[21]. In contrast, others were unable to confirm an enhanced
proliferation through activation of BK channels in MCF7 [23].
Notably, one report showed a role for KCNMA1 in breast cancer
invasion and metastasis to brain [38].
We found an inverse association between KCNMA1 amplifica-
tion and AR expression. Almost all (8 of 9; 89%) KCNMA1
amplified, but only 11 of 25 (44%) non-amplified breast cancers
were AR-negative. The role of AR in breast cancer has not yet
been fully elucidated, but it has been postulated that AR has an
anti-proliferative and favourable prognostic effect in ER-positive
breast cancer, whereas it has a growth-stimulating and unfavour-
able prognostic effect in ER-negative breast cancer [39].
It has previously been demonstrated that not only 17b-estradiol
but also testosterone can relax smooth muscle by potentiating BK
channels [40]. Responsiveness to these sex hormones could
explain why BK channel up-regulation and KCNMA1 amplifica-
tion occur in hormone-regulated cancers. Further studies are
needed to elucidate the complex interplay between sex hormones
and KCNMA1 in breast- and prostate cancer that is likely to be
influenced by the type of regulatory ß-subunits of the BK channel,
alternative splicing, the background of ER and/or AR status, and
anti-hormone therapy.
Unfortunately, there is currently no reliable antibody for
formalin-fixed and paraffin-embedded material. Therefore, we
could not test the prevalence and significance of KCNMA1
protein expression in a large number of clinical cancer specimens.
Figure 7. Effect paxilline on cell morphology. Cell shape of
MFM223 cells before (A) and after the treatmentwith 15 mMKCNMA1blocker
paxilline (B and C). Images show cells at 206(A, B) and 406(C) magnification.
doi:10.1371/journal.pone.0041664.g007
Figure 8. KCNMA1 currents in MCF7 and MFM223 cells. A)
Continued whole cell current recording shows the activation of whole
cell currents by 17b-estradiol (10 mM) in a MFM223 cell. B) Summary of
the whole cell conductance activated in MCF7 and MFM223 cells by two
different concentrations of 17b-estradiol (10 nM and 10 mM). C,D)
Current/voltage relationships for MCF7 and MFM223 cells under control
conditions and after stimulation with 17b-estradiol. E) Continued whole
cell current recording shows the activation of whole cell currents by
NS1619 (10 mM) in a MFM223 cell, and the inhibition of the NS1619-
activated current by paxilline (Pax, 5 mM). F) Summary of the whole cell
conductance activated by NS1619 in MCF7 and MFM223 cells and
inhibition of the whole cell current by paxilline. Mean 6 SEM,
(n) = number of cells measured. *significant stimulation by 17b-estradiol
or NS1619 (paired t-test). # significant difference when compared to
MCF7 cells (unpaired t-test).
doi:10.1371/journal.pone.0041664.g008
Figure 9. Suppression of KCNMA1 in MCF7 and MFM223 cells
by siRNA. A) Whole cell currents in non-transfected MCF7 cells and
cells transfected with nsRNAi (control) and siRNA targeting KCNMA1. B)
Whole cell currents in: non-transfected MFM223 cells and cells
transfected with nsRNAi and siRNA targeting KCNMA1. C) Summary of
the whole cell conductance activated by 17b-estradiol (10 mM) in MCF7
and MFM223 cells and inhibition of the whole cell currents by siRNA
against KCNMA1. Mean 6 SEM, (n) = number of cells measured.
1significant difference when compared to MCF7 cells (unpaired t-test).
# significant difference when compared to cells treated with scrambled
RNAi (unpaired t-test).
doi:10.1371/journal.pone.0041664.g009
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However, immunofluorescence revealed moderate to strong
KCNMA1 expression in eight out of nine frozen breast cancer
specimens irrespectively of KCNMA1 gene copy number. Thus, the
presence of the KCNMA1 amplification in tumour specimens and
MFM223 might rather highlight KCNMA1 as a gene with
oncogenic relevance, while mechanisms other than amplification
seem to be responsible for KCNMA1 overexpression in most of
these tumours.
In conclusion, we report for the first time that KCNMA1
amplification occurs in carcinomas of the breast, ovary and
endometrium. The prevalence of the amplification across different
human cancer types points towards a broader general oncogenic
potential of KCNMA1 than previously assumed.
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